K
95.03
4.35 (4.80%)
| Previous Close | 90.68 |
| Open | 86.00 |
| Volume | 1,246,269 |
| Avg. Volume (3M) | 992,155 |
| Market Cap | 7,602,307,072 |
| Price / Sales | 182.36 |
| Price / Book | 4.37 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Operating Margin (TTM) | -336.77% |
| Diluted EPS (TTM) | -3.11 |
| Quarterly Revenue Growth (YOY) | 114.80% |
| Total Debt/Equity (MRQ) | 10.98% |
| Current Ratio (MRQ) | 8.49 |
| Operating Cash Flow (TTM) | -234.06 M |
| Levered Free Cash Flow (TTM) | -136.32 M |
| Return on Assets (TTM) | -19.47% |
| Return on Equity (TTM) | -32.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Kymera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-1.0
| Analyst Consensus | 4.0 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -1.00 |
|
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.50% |
| % Held by Institutions | 104.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 140.00 (Piper Sandler, 47.32%) | Buy |
| Median | 124.00 (30.49%) | |
| Low | 100.00 (Stephens & Co., 5.23%) | Buy |
| Average | 121.88 (28.25%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 87.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 03 Mar 2026 | 128.00 (34.69%) | Buy | 86.35 |
| Citigroup | 02 Mar 2026 | 120.00 (26.28%) | Buy | 90.10 |
| Stephens & Co. | 02 Mar 2026 | 100.00 (5.23%) | Buy | 90.10 |
| BTIG | 26 Feb 2026 | 134.00 (41.01%) | Buy | 95.03 |
| 03 Feb 2026 | 138.00 (45.22%) | Buy | 77.22 | |
| Piper Sandler | 26 Feb 2026 | 140.00 (47.32%) | Buy | 95.03 |
| Barclays | 28 Jan 2026 | 133.00 (39.96%) | Buy | 71.16 |
| B. Riley Securities | 22 Dec 2025 | 117.00 (23.12%) | Buy | 84.35 |
| RBC Capital | 16 Dec 2025 | 103.00 (8.39%) | Buy | 84.19 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADAMS BRIAN | 90.10 | - | 4,125 | 371,663 |
| BOOTH BRUCE | - | 90.10 | -81,866 | -7,376,127 |
| CHADWICK JEREMY G | 90.10 | 88.11 | 6,617 | 611,829 |
| GOLLOB JARED | 90.10 | 88.11 | 7,142 | 663,025 |
| GOODMAN NOAH | 90.10 | - | 9,225 | 831,173 |
| JACOBS BRUCE N. | 90.10 | 88.11 | 5,179 | 486,159 |
| Aggregate Net Quantity | -49,578 | |||
| Aggregate Net Value ($) | -4,412,279 | |||
| Aggregate Avg. Buy ($) | 90.10 | |||
| Aggregate Avg. Sell ($) | 88.39 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JACOBS BRUCE N. | Officer | 04 Mar 2026 | Sell (-) | 4,895 | 86.11 | 421,508 |
| GOLLOB JARED | Officer | 04 Mar 2026 | Sell (-) | 4,895 | 86.11 | 421,508 |
| CHADWICK JEREMY G | Officer | 04 Mar 2026 | Sell (-) | 3,919 | 86.11 | 337,465 |
| BOOTH BRUCE | Director | 02 Mar 2026 | Automatic sell (-) | 81,866 | 90.10 | 7,376,127 |
| ADAMS BRIAN | Officer | 02 Mar 2026 | Acquired (+) | 4,125 | 90.10 | 371,663 |
| JACOBS BRUCE N. | Officer | 02 Mar 2026 | Acquired (+) | 17,650 | 90.10 | 1,590,265 |
| JACOBS BRUCE N. | Officer | 02 Mar 2026 | Sell (-) | 7,576 | 90.10 | 682,598 |
| GOLLOB JARED | Officer | 02 Mar 2026 | Acquired (+) | 17,650 | 90.10 | 1,590,265 |
| GOLLOB JARED | Officer | 02 Mar 2026 | Sell (-) | 5,613 | 90.10 | 505,731 |
| GOODMAN NOAH | Officer | 02 Mar 2026 | Acquired (+) | 9,225 | 90.10 | 831,173 |
| CHADWICK JEREMY G | Officer | 02 Mar 2026 | Acquired (+) | 12,575 | 90.10 | 1,133,008 |
| CHADWICK JEREMY G | Officer | 02 Mar 2026 | Sell (-) | 2,039 | 90.10 | 183,714 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Kymera Therapeutics to Participate in Upcoming February Investor Conferences |
| 29 Jan 2026 | Announcement | Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader |
| 13 Jan 2026 | Announcement | Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs |
| 06 Jan 2026 | Announcement | Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |